General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0IKQCL
ADC Name
H2-921
Synonyms
Trastuzume -VA-SB743921
   Click to Show/Hide
Organization
Academy of Military Medicine, PLA Academy of Military Sciences
Drug Status
Investigative
Drug-to-Antibody Ratio
4.66
Structure
Antibody Name
Trastuzumab
 Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
 Antigen Info 
Payload Name
SB743921
 Payload Info 
Therapeutic Target
Kinesin spindle protein (KSP)
 Target Info 
Linker Name
CN118987256A, H2-921, Linker
 Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
Linker+SB743921 (D7)
ADC-specific functional property(2027 Update)
Circulating Stability
Click To Hide/Show 3 ADC-specific functional property Data
Incubation Time 7day Release <10ng/mL Reference
[1]
Incubation Medium H2-921 was dissolved in human plasma (initial concentration of H2-921 was 400ug/ml in human plasma), and incubated at 37 °C for 7 days. Samples were taken at the predetermined time (0.0833, 0.5, 1, 4, 8, 12, 24, 48, 96, 168h) and the content of free SB743921 in plasma was determined by LC-MS/MS method.
Description
H2-921 can significantly prolong SB743921 in serum of different species Half-life period.
Incubation Time 7day Release <10ng/mL Reference
[1]
Incubation Medium H2-921 was dissolved in monkey plasma (initial concentration of H2-921 was 400ug/ml in monkey plasma), and incubated at 37 °C for 7 days. Samples were taken at the predetermined time (0.0833, 0.5, 1, 4, 8, 12, 24, 48, 96, 168h) and the content of free SB743921 in plasma was determined by LC-MS/MS method.
Description
H2-921 can significantly prolong SB743921 in serum of different species Half-life period.
Incubation Time 8hr Release ≈80ng/mL Reference
[1]
Incubation Medium H2-921 was dissolved in lysosomal system (0.02 mg/ml of lysosomal PBS buffer), initial concentration of H2-921 was 20ug/ml in lysosomal system, and incubated at 37 °C for 7 days. Samples were taken at the predetermined time (0.0833, 0.5, 1, 4, 8, 12, 24, 48, 96, 168h) and the content of free SB743921 in plasma was determined by LC-MS/MS method.
Description
H2-921 can significantly prolong SB743921 in serum of different species Half-life period.
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth lnhibition value (TGl) 
≈ 73.3
%
Undisclosed Undisclosed
Tumor Growth lnhibition value (TGl) 
≈ 83.3
%
Undisclosed Undisclosed
Tumor Growth lnhibition value (TGl) 
≈ 99.6
%
Undisclosed Undisclosed
Revealed Based on the Cell Line Data
Click To Hide/Show 13 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50)  .
log10 ng/mL
CVCL_0179
Invasive breast carcinoma
Half Maximal inhibitory Concentration (lC50)  .
log10 ng/mL
CVCL_5546
Normal
Half Maximal inhibitory Concentration (lC50)  .
log10 ng/mL
CVCL_EQ22
Normal
Half Maximal inhibitory Concentration (lC50)  .
log10 ng/mL
CVCL_0419
Breast adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
1.8
log10 ng/mL
CVCL_0532
Ovarian serous adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
3.5
log10 ng/mL
CVCL_0033
Breast adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
5
log10 ng/mL
CVCL_1603
Gastric tubular adenocarcinoma
apoptosis 
24.05
%
CVCL_0532
Ovarian serous adenocarcinoma
apoptosis 
38.19
%
CVCL_1603
Gastric tubular adenocarcinoma
apoptosis 
51.63
%
CVCL_1603
Gastric tubular adenocarcinoma
apoptosis 
58.87
%
CVCL_1603
Gastric tubular adenocarcinoma
apoptosis 
78.59
%
CVCL_0532
Ovarian serous adenocarcinoma
apoptosis 
82.56
%
CVCL_0532
Ovarian serous adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) ≈ 73.30% Positive HER2 expression (HER2+++/++)
Method Description
Female nude mice (5 ~ 6 weeks old, weight about 20g) were included in the experiment after 1 week of adaptive feeding. It's going to be about 5 x 10Six SKOV-3 cells were inoculated under the skin of the right hind limb of mice to observe the tumor formation. When the tumor volume reached 120mm3, the mice were randomly divided into treatment group and control group (n = 6 groups). H2-921 at 0.5 mg/kg, T-DM1 (1.5 mg/kg, positive control) and PBS (control) were administered at day 0, 7 and 14, respectively. Animal weight was monitored every 3 days and animal behavior was observed daily.Tumor volume was monitored every 3 days during treatment and calculated using the formula TV = a× B2/3, where a represents the long diameter of each tumor and b represents the short diameter of each tumor.

   Click to Show/Hide
In Vivo Model SKOV3 tumor bearing female nude mouse model
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) ≈ 83.30% Positive HER2 expression (HER2+++/++)
Method Description
Female nude mice (5 ~ 6 weeks old, weight about 20g) were included in the experiment after 1 week of adaptive feeding. It's going to be about 5 x 10Six SKOV-3 cells were inoculated under the skin of the right hind limb of mice to observe the tumor formation. When the tumor volume reached 120mm3, the mice were randomly divided into treatment group and control group (n = 6 groups). H2-921 at 1.5 mg/kg, T-DM1 (1.5 mg/kg, positive control) and PBS (control) were administered at day 0, 7 and 14, respectively. Animal weight was monitored every 3 days and animal behavior was observed daily.Tumor volume was monitored every 3 days during treatment and calculated using the formula TV = a× B2/3, where a represents the long diameter of each tumor and b represents the short diameter of each tumor.

   Click to Show/Hide
In Vivo Model SKOV3 tumor bearing female nude mouse model
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) ≈ 99.60% Positive HER2 expression (HER2+++/++)
Method Description
Female nude mice (5 ~ 6 weeks old, weight about 20g) were included in the experiment after 1 week of adaptive feeding. It's going to be about 5 x 10Six SKOV-3 cells were inoculated under the skin of the right hind limb of mice to observe the tumor formation. When the tumor volume reached 120mm3, the mice were randomly divided into treatment group and control group (n = 6 groups). H2-921 at 4.5 mg/kg, T-DM1 (1.5 mg/kg, positive control) and PBS (control) were administered at day 0, 7 and 14, respectively. Animal weight was monitored every 3 days and animal behavior was observed daily.Tumor volume was monitored every 3 days during treatment and calculated using the formula TV = a× B2/3, where a represents the long diameter of each tumor and b represents the short diameter of each tumor.

   Click to Show/Hide
In Vivo Model SKOV3 tumor bearing female nude mouse model
Revealed Based on the Cell Line Data
Click To Hide/Show 13 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) . log10 ng/mL Positive HER2 expression (HER2+++/++)
Method Description
BT-474 cells were inoculated in 96-well plates with 5×103 cells/wells and cultured overnight at 37°C with 5% CO2. Then trastuzumab, SB743921, linker+SB743921 or H were added at concentrations of 100ug/ml, 10ug/ml, 1ug/ml, 100ng/ml, 10ng/ml, 1ng/ml, 100pg/ml, 10pg/ml, 1pg/ml or 0mg/ml, respectively 2-921. After culture at 37°C and 5% CO2 for 48h, 10ul CCK-8 solution was added to each well. After 2 ~ 4h, the absorbance at 450nm was measured by enzymograph, and the cell survival rate was calculated.

   Click to Show/Hide
In Vitro Model Invasive breast carcinoma BT-474 cells CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) . log10 ng/mL Negative HER2 expression (HER2-)
Method Description
IOSE80 cells were inoculated in 96-well plates with 5×103 cells/wells and cultured overnight at 37°C with 5% CO2. Then trastuzumab, SB743921, linker+SB743921 or H were added at concentrations of 100ug/ml, 10ug/ml, 1ug/ml, 100ng/ml, 10ng/ml, 1ng/ml, 100pg/ml, 10pg/ml, 1pg/ml or 0mg/ml, respectively 2-921. After culture at 37°C and 5% CO2 for 48h, 10ul CCK-8 solution was added to each well. After 2 ~ 4h, the absorbance at 450nm was measured by enzymograph, and the cell survival rate was calculated.

   Click to Show/Hide
In Vitro Model Normal IOSE80 cells CVCL_5546
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) . log10 ng/mL Negative HER2 expression (HER2-)
Method Description
GES-1 cells were inoculated in 96-well plates with 5×103 cells/Wells and cultured overnight at 37°C with 5% CO2. Then trastuzumab, SB743921, linker+SB743921 or H were added at concentrations of 100ug/ml, 10ug/ml, 1ug/ml, 100ng/ml, 10ng/ml, 1ng/ml, 100pg/ml, 10pg/ml, 1pg/ml or 0mg/ml, respectively 2-921. After culture at 37°C and 5% CO2 for 48h, 10ul CCK-8 solution was added to each well. After 2 ~ 4h, the absorbance at 450nm was measured by enzymograph, and the cell survival rate was calculated.

   Click to Show/Hide
In Vitro Model Normal GES-1 cells CVCL_EQ22
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) . log10 ng/mL Negative HER2 expression (HER2-)
Method Description
MDA-MB-468 cells were inoculated in 96-well plates with 5×103 cells/wells and cultured overnight at 37°C with 5% CO2. Then trastuzumab, SB743921, linker+SB743921 or H were added at concentrations of 100ug/ml, 10ug/ml, 1ug/ml, 100ng/ml, 10ng/ml, 1ng/ml, 100pg/ml, 10pg/ml, 1pg/ml or 0mg/ml, respectively 2-921. After culture at 37°C and 5% CO2 for 48h, 10ul CCK-8 solution was added to each well. After 2 ~ 4h, the absorbance at 450nm was measured by enzymograph, and the cell survival rate was calculated.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma MDA-MB-468 cells CVCL_0419
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 1.8 log10 ng/mL Positive HER2 expression (HER2+++/++)
Method Description
SKOV-3 cells were inoculated in 96-well plates at 5×103 cells/wells and cultured overnight at 37°C with 5% CO2. Then trastuzumab, SB743921, linker+SB743921 or H were added at concentrations of 100ug/ml, 10ug/ml, 1ug/ml, 100ng/ml, 10ng/ml, 1ng/ml, 100pg/ml, 10pg/ml, 1pg/ml or 0mg/ml, respectively 2-921. After culture at 37°C and 5% CO2 for 48h, 10ul CCK-8 solution was added to each well. After 2 ~ 4h, the absorbance at 450nm was measured by enzymograph, and the cell survival rate was calculated.

   Click to Show/Hide
In Vitro Model Ovarian serous adenocarcinoma SKOV-3 cells CVCL_0532
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 3.5 log10 ng/mL Positive HER2 expression (HER2+++/++)
Method Description
SK-BR-3 cells were inoculated in 96-well plates with 5×103 cells/wells and cultured overnight at 37°C with 5% CO2. Then trastuzumab, SB743921, linker+SB743921 or H were added at concentrations of 100ug/ml, 10ug/ml, 1ug/ml, 100ng/ml, 10ng/ml, 1ng/ml, 100pg/ml, 10pg/ml, 1pg/ml or 0mg/ml, respectively 2-921. After culture at 37°C and 5% CO2 for 48h, 10ul CCK-8 solution was added to each well. After 2 ~ 4h, the absorbance at 450nm was measured by enzymograph, and the cell survival rate was calculated.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 5 log10 ng/mL Positive HER2 expression (HER2+++/++)
Method Description
NCI-N87 were inoculated in 96-well plates at 5×103 cells/wells and cultured overnight at 37°C with 5% CO2. Then trastuzumab, SB743921, linker+SB743921 or H were added at concentrations of 100ug/ml, 10ug/ml, 1ug/ml, 100ng/ml, 10ng/ml, 1ng/ml, 100pg/ml, 10pg/ml, 1pg/ml or 0mg/ml, respectively 2-921. After culture at 37°C and 5% CO2 for 48h, 10ul CCK-8 solution was added to each well. After 2 ~ 4h, the absorbance at 450nm was measured by enzymograph, and the cell survival rate was calculated.

   Click to Show/Hide
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data apoptosis 24.05% Positive HER2 expression (HER2+++/++)
Method Description
SKOV-3 cells were inoculated in 6-well plates at about 1×106 cells per well and incubated overnight at 37°C with 5% CO2. The cells were then treated with 1 ug/ml H2-921 for 48 hours. The cells were then collected, suspended with pre-cooled 70% alcohol and fixed overnight at 4 °C. The cells were then incubated with RNase A at 37 °C, RNase A was removed again, and the cells were suspended with propyl iodide (PI) staining solution. 30min dull staining and FACSCalibur flow cytometry. For apoptosis analysis, the cells were treated as described above, and apoptosis was detected by Annexin V-FITC/PI double staining apoptosis kit (Dojindo, Japan) after 48h. Cell cycle distribution and apoptosis were detected by FACSCalibur flow cytometry.

   Click to Show/Hide
In Vitro Model Ovarian serous adenocarcinoma SKOV-3 cells CVCL_0532
Experiment 9 Reporting the Activity Date of This ADC [1]
Efficacy Data apoptosis 38.19% Positive HER2 expression (HER2+++/++)
Method Description
NCI-N87 cells were inoculated in 6-well plates at about 1×106 cells per well and incubated overnight at 37°C with 5% CO2. The cells were then treated with 1 ug/ml H2-921 for 48 hours. The cells were then collected, suspended with pre-cooled 70% alcohol and fixed overnight at 4 °C. The cells were then incubated with RNase A at 37 °C, RNase A was removed again, and the cells were suspended with propyl iodide (PI) staining solution. 30min dull staining and FACSCalibur flow cytometry. For apoptosis analysis, the cells were treated as described above, and apoptosis was detected by Annexin V-FITC/PI double staining apoptosis kit (Dojindo, Japan) after 48h. Cell cycle distribution and apoptosis were detected by FACSCalibur flow cytometry.

   Click to Show/Hide
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
Experiment 10 Reporting the Activity Date of This ADC [1]
Efficacy Data apoptosis 51.63% Positive HER2 expression (HER2+++/++)
Method Description
NCI-N87 cells were inoculated in 6-well plates at about 1×106 cells per well and incubated overnight at 37°C with 5% CO2. The cells were then treated with 10 ug/ml H2-921 for 48 hours. The cells were then collected, suspended with pre-cooled 70% alcohol and fixed overnight at 4 °C. The cells were then incubated with RNase A at 37 °C, RNase A was removed again, and the cells were suspended with propyl iodide (PI) staining solution. 30min dull staining and FACSCalibur flow cytometry. For apoptosis analysis, the cells were treated as described above, and apoptosis was detected by Annexin V-FITC/PI double staining apoptosis kit (Dojindo, Japan) after 48h. Cell cycle distribution and apoptosis were detected by FACSCalibur flow cytometry.

   Click to Show/Hide
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
Experiment 11 Reporting the Activity Date of This ADC [1]
Efficacy Data apoptosis 58.87% Positive HER2 expression (HER2+++/++)
Method Description
NCI-N87 cells were inoculated in 6-well plates at about 1×106 cells per well and incubated overnight at 37°C with 5% CO2. The cells were then treated with 100 ug/ml H2-921 for 48 hours. The cells were then collected, suspended with pre-cooled 70% alcohol and fixed overnight at 4 °C. The cells were then incubated with RNase A at 37 °C, RNase A was removed again, and the cells were suspended with propyl iodide (PI) staining solution. 30min dull staining and FACSCalibur flow cytometry. For apoptosis analysis, the cells were treated as described above, and apoptosis was detected by Annexin V-FITC/PI double staining apoptosis kit (Dojindo, Japan) after 48h. Cell cycle distribution and apoptosis were detected by FACSCalibur flow cytometry.

   Click to Show/Hide
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
Experiment 12 Reporting the Activity Date of This ADC [1]
Efficacy Data apoptosis 78.59% Positive HER2 expression (HER2+++/++)
Method Description
SKOV-3 cells were inoculated in 6-well plates at about 1×106 cells per well and incubated overnight at 37°C with 5% CO2. The cells were then treated with 10 ug/ml H2-921 for 48 hours. The cells were then collected, suspended with pre-cooled 70% alcohol and fixed overnight at 4 °C. The cells were then incubated with RNase A at 37 °C, RNase A was removed again, and the cells were suspended with propyl iodide (PI) staining solution. 30min dull staining and FACSCalibur flow cytometry. For apoptosis analysis, the cells were treated as described above, and apoptosis was detected by Annexin V-FITC/PI double staining apoptosis kit (Dojindo, Japan) after 48h. Cell cycle distribution and apoptosis were detected by FACSCalibur flow cytometry.

   Click to Show/Hide
In Vitro Model Ovarian serous adenocarcinoma SKOV-3 cells CVCL_0532
Experiment 13 Reporting the Activity Date of This ADC [1]
Efficacy Data apoptosis 82.56% Positive HER2 expression (HER2+++/++)
Method Description
SKOV-3 cells were inoculated in 6-well plates at about 1×106 cells per well and incubated overnight at 37°C with 5% CO2. The cells were then treated with 100 ug/ml H2-921 for 48 hours. The cells were then collected, suspended with pre-cooled 70% alcohol and fixed overnight at 4 °C. The cells were then incubated with RNase A at 37 °C, RNase A was removed again, and the cells were suspended with propyl iodide (PI) staining solution. 30min dull staining and FACSCalibur flow cytometry. For apoptosis analysis, the cells were treated as described above, and apoptosis was detected by Annexin V-FITC/PI double staining apoptosis kit (Dojindo, Japan) after 48h. Cell cycle distribution and apoptosis were detected by FACSCalibur flow cytometry.

   Click to Show/Hide
In Vitro Model Ovarian serous adenocarcinoma SKOV-3 cells CVCL_0532
References
Ref 1 Antibody-drug conjugates and their preparation methods and uses